Background and aims
Mucin 5AC (MUC5AC) is a glycoprotein found in different epithelial cancers, including biliary tract cancer (BTC). The aims of this study were to investigate the role of MUC5AC as serum marker for BTC and its prognostic value after operation with curative intent.
Patients and method
From January 2007 to July 2012, a quantitative assessment of serum MUC5AC was performed with enzyme-linked immunoassay in a total of 88 subjects. Clinical and biochemical data (including CEA and Ca 19-9) of 49 patients with BTC were compared with a control population that included 23 patients with benign biliary disease (BBD) and 16 healthy control subjects (HCS).
Serum MUC5AC was greater in BTC patients (mean 17.93 ± 10.39 ng/mL) compared with BBD (mean 5.95 ± 5.39 ng/mL; P < .01) and HCS (mean 2.74 ± 1.35 ng/mL) (P < .01). Multivariate analysis showed that MUC5AC was related with the presence of BTC compared with Ca 19-9 and CEA: P < .01, P = .080, and P = .463, respectively. In the BTC group, serum MUC5AC ≥14 ng/mL was associated with lymph-node metastasis (P = .050) and American Joint Committee on Cancer and International Union for Cancer Control stage IVb disease (P = .047). Moreover, in patients who underwent operation with curative intent, serum MUC5AC ≥14 ng/mL was related to a worse prognosis compared with patients with lesser levels, with 3-year survival rates of 21.5% and 59.3%, respectively (P = .039).
MUC5AC could be proposed as new serum marker for BTC. Moreover, the quantitative assessment of serum MUC5AC could be related to tumor stage and long-term survival in patients with BTC undergoing operation with curative intent.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Biliary tract cancers.N Engl J Med. 1999; 341: 1368-1378
- Cholangiocarcinoma.Lancet. 2005; 366: 1303-1314
- Surgical management of cholangiocarcinoma.Semin Liver Dis. 2004; 24: 189-199
- Cholangiocarcinoma: current concepts and insights.Hepatology. 2003; 37: 961-969
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.Gut. 2002; 51: VI1-VI9
- Endoscopic management of cholangiocarcinoma.Semin Liver Dis. 2004; 24: 165-175
- Serum and bile markers for cholangiocarcinoma.Semin Liver Dis. 2004; 24: 139-154
- The MUC family: an obituary.Trends Biochem Sci. 2002; 27: 126-131
- Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases.Biochim Biophys Acta. 2006; 1765: 189-222
- Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance.Prog Histochem Cytochem. 2007; 42: 61-110
- Heterogeneity of mucin gene expression in normal and neoplastic tissues.Cancer Res. 1993; 53: 641-651
- Biliary epithelial expression of MUC1, MUC2, MUC3 and MUC5/6 apomucins during intrahepatic bile duct development and maturation. An immunohistochemical study.Am J Pathol. 1995; 147: 574-579
- MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.Br J Cancer. 2008; 98: 1675-1681
- The expression of MUC mucin in cholangiocarcinoma.Pathol Res Pract. 2010; 206: 805-809
- Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder.J Surg Oncol. 2011; 105: 97-103
- Serum MUC5AC mucin as a potential marker for cholangiocarcinoma.Cancer Lett. 2003; 195: 93-99
- Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma.Cancer. 2003; 98: 1438-1443
- The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2:333–39.HPB (Oxford). 2002; 4 (author reply 100): 99
- Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer.Ann Surg Oncol. 2011; 18: 1651-1656
- Identification of a novel biomarker for biliary tract cancer using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Int J Proteomics. 2012; 2012: 108609
- Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.Cancer. 2012; 119: 575-585
- Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?.J Surg Oncol. 2010; 101: 111-115
- Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients.Arch Surg. 2012; 20: 1-7
- Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.Arch Surg. 2012; 147: 26-34
- A step forward in the treatment of advanced biliary tract cancer.N Engl J Med. 2010; 362: 1335-1337
- Tumor markers as a diagnostic key for hilar cholangiocarcinoma.Eur J Med Res. 2010; 15: 357-361
- Expression of mucin antigens in human cancers and its relationship with malignancy potential.Pathol Int. 1997; 47: 813-830
- Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact.Oncol Rep. 2009; 22: 649-657
- CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.Liver. 1999; 19: 501-508
- Measurement of serum CA 19-9 in biliary diseases requires great caution.Acta Oncol. 2001; 40: 877-878
- CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.Am J Surg. 2009; 198: 333-339
- Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.Cancer Cytopathol. 2013; 121: 708-717
Published online: December 16, 2013
Accepted: December 6, 2013
© 2014 Mosby, Inc. Published by Elsevier Inc. All rights reserved.